Application Area: Heart Disease
40 Results for 'Heart Disease'
- Technologies (6)
- Team (0)
- News (26)
- Events (0)
- Jobs (0)
- Publications (0)
- Multimedia (8)
Technologies 6
-
Regenerating heart valves
The human heart beats approximately 35 million times every year, pumping blood into the circulation via four different heart valves. In more than four million people each year, heart valves fail for different reasons, including birth defects, age-related deteriorations and infections. At present, clinicians use either artificial prostheses or fixed animal and cadaver-sourced tissue to... -
AAV-Engineering For Advanced Gene Therapy
Gene therapy with AAV (adeno-associated virus) as a delivery vehicle is a leading therapeutic modality for genetic disorders that is approved in Europe for the metabolic disease Familial Lipoprotein Lipase Deficiency. It is currently being tested in clinical trials in the U.S. to treat other rare conditions like the retinal Leber Congenital Amaurosis and the... -
A broad strategy to reduce the toxicity of protein drugs
Therapeutic variants of the natural hormone erythropoietin (EPO) which is produced in the kidney to boost the production of red blood cells are commonly used to treat anemias stemming from kidney disease, chemotherapy and other complications. However, many drugs that are based on therapeutic proteins, including EPO, often cause unwanted side effects because they not... -
Mechanically-Activated Drug Targeting Nanotechnology
The Wyss team has developed a novel drug targeting nanotechnology that is activated locally by mechanical forces, either endogenous high shear stresses in blood created by vascular occlusion or mechanical energy applied locally using low-energy ultrasound radiation. Today, vascular blockage is the leading cause of death and disability in United States and Europe. Current therapies... -
Human Organs-on-Chips
Clinical studies take years to complete and testing a single compound can cost more than $2 billion. Meanwhile, innumerable animal lives are lost, and the process often fails to predict human responses because traditional animal models often do not accurately mimic human pathophysiology. For these reasons, there is a broad need for alternative ways to... -
Microfluidic Hemostasis Monitor
The body’s ability to stop bleeding, also known as hemostasis, is critical for survival. For patients with blood clotting disorders, medical conditions requiring the use of anticoagulation or antiplatelet drugs, or who require treatment with extracorporeal devices that circulate their blood outside of the body, it is essential that care providers can rapidly monitor their...
News 26
Multimedia 8
-
Video/AnimationSoft Robotic Heart Sleeve: In VitroReplicating heart pressure and contraction in vitro, the soft robotic heart sleeve with actuators arranged around a fluid-filled sac is able to rhythmically contract to each time pump a defined fluid volume into the attached tubing. Credit: Harvard SEAS -
Video/Animation3D Printed Heart-on-a-ChipIn this video, learn how Wyss Institute and Harvard SEAS researchers have created a 3D-printed heart-on-a-chip that could lead to new customizable devices for short-term and long-term in vitro testing. Credit: Johan U. Lind (Disease Biophysics Group), Alex D. Valentine and Lori K. Sanders (Lewis Lab)/Harvard University -
Video/AnimationHuman Organs-On-ChipsWyss Institute researchers and a multidisciplinary team of collaborators have engineered microchips that recapitulate the microarchitecture and functions of living human organs, including the lung, intestine, kidney, skin, bone marrow and blood-brain barrier. These microchips, called ‘organs-on-chips’, offer a potential alternative to traditional animal testing. Each individual organ-on-chip is composed of a clear flexible polymer... -
Video/AnimationBioinspired Blood Repellent CoatingIn this video, Wyss Institute Founding Director Don Ingber, Core Faculty member Joanna Aizenberg, Staff Scientist Dan Leslie and Postdoctoral Fellow Anna Waterhouse explain how a coating they developed using FDA-approved materials could prevent blood clotting in medical devices without the use of blood thinners. Credit: Wyss Institute at Harvard University -
Video/AnimationNanoRx: Clot-Busting NanotherapeuticIn this animation, learn how the Wyss Institute clot-busting nanotherapeutic is activated by fluid high shear force – which occurs where blood flows through vessels narrowed by obstruction – to specifically target clots and dissolve them away. By pairing this drug with an intra-arterial device that restores blood flow to complete obstructions, the drug-device combination...
-
Video/AnimationMeTro HydrogelsAn international team led by the Wyss Institute recently used microfabrication techniques to design a new micropatterned hydrogel that shows great promise for tissue engineering — cardiac tissue in particular. It incorporates an elastic protein called tropoelastin, which is found in all elastic human tissues. The Wyss Institute’s Ali Khademhosseini discusses the research. Credit: Wyss...